Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Neo

Mid-Afternoon Market Update: Dow Surges 250 Points; NeoGenomics Shares Slide

U.S. stocks traded higher toward the end of trading, with the Dow jumping over 250 points on Tuesday.

Psyched: Third Michigan City Decriminalizes Psychedelics, MindMed Reports $133M Cash Position, Real Brands To Enter The Space

Psyched: Third Michigan City Decriminalizes Psychedelics, MindMed Reports $133M Cash Position, Real Brands To Enter The Space

The psychedelics legislative landscape continues to move forward with Hazel Park, Michigan enacting decriminalization measures for naturally-produced psychedelic molecules, becoming the third city in the state to do so after Ann Arbor and Detroit. In Utah, Governor Cox signed a psychedelics research bill into law and positive legislation around psilocybin is continuing…

NeoGenomics Stock Tanks After CEO Exits Amid Sales, Profitability Maelstrom

NeoGenomics Stock Tanks After CEO Exits Amid Sales, Profitability Maelstrom

NeoGenomics CEO Mark Mallon stepped down Tuesday and the company expects light first-quarter results, leading NEO stock to tank.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why NeoGenomics Stock Is Plunging Today

NeoGenomics Inc's (NASDAQ:NEO) CEO Mark Mallon will step down as CEO and member of the Board, effective immediately. The Board has retained Russell Reynolds to search for the Company's next CEO The Board has appointed current Chair Lynn Tetrault, Esq. as Executive Chair and established an Interim Office of the CEO. Read…

10 Biggest Price Target Changes For Tuesday

BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading.

Where NeoGenomics Stands With Analysts

Over the past 3 months, 8 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia

Here's a roundup of top developments in the biotech space over the last 24 hours:

inkl

Read news from The Economist, FT, and more,
with one subscription

MindMed Reports Full Year 2021 Financial Results, Announces Changes In Leadership

MindMed Reports Full Year 2021 Financial Results, Announces Changes In Leadership

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED) reported its financial results for the full year ended December 31, 2021. 2021 Financial Results Cash balance as of December 31, 2021, was $133.5 million compared to $80.1 million as of December 31, 2020. Net cash in operating activities was $45.8 million for…

EXCLUSIVE: Here's Why Investments In WonderFi Are 'A Global Play'

EXCLUSIVE: Here's Why Investments In WonderFi Are 'A Global Play'

Earlier this year, WonderFi Technologies Inc (NEO: WNDR) announced its intention to acquire First Ledger Corporation, the parent of Bitbuy, the first approved crypto marketpl

Schwazze Gains Access To Wider Investor Exposure As It Debuts On NEO Exchange

Schwazze Gains Access To Wider Investor Exposure As It Debuts On NEO Exchange

NEO revealed on Wednesday that Medicine Man Technologies, Inc. operating as Schwazze (OTC: SHWZ) is listing on the NEO Exchange.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

Compass Pathways

House Committee

Psychedelic Spotlight

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

251,633 stories

105,362 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play